Research

Clinuvel has conducted over 15 trials of SCENESSE® (afamelanotide) in over 600 patients, published research from which can be purchased online.

Below is a selection of published research on SCENESSE®.

The links above direct you to sites outside of the control of Clinuvel which are not produced or endorsed by Clinuvel.

Over 200 articles have been published on afamelanotide (chemical name [Nle4, D-Phe7]α-MSH or NDP-MSH).

SCENESSE® Blog Posts

In what has become something of a tradition in recent years, yet another country has used the new year to adopt further laws related to...

Read More

Allergan’s lawsuit filed against the FDA presents a relatively novel case in addressing the requirements of drug developers in relation...

Read More

Following on from last week’s conversation, I left off with the issues surrounding the off-label prescriptive habits by physicians and...

Read More

SCENESSE® Webcasts

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now